Hongming Chen
Founder
Now Founder, METiS TechBio
Latest on AI4S.fyiFunding · May 13 · founderMETiS TechBio · IPO · about HK$2.113B grossPhotos come from each person's X account, their own site, lab or team page, a conference page that lists them as a speaker in the same role, or Wikimedia Commons under the licence credited, so some may be out of date. Anyone can ask for theirs to be replaced or removed. Contact →
Affiliations
Current
- Founder · METiS TechBio
Current roles come from these dated records, not from the bio below. Each links the page it was read from.
About
Hongming Chen is a co-founder of METiS TechBio and its chief R&D officer. She worked at Merck and at AstraZeneca R&D Boston, co-founded Transform Pharmaceuticals, and was chief scientific officer at Kala Pharmaceuticals. She holds a PhD in chemical engineering from MIT and is a member of the US National Academy of Engineering.
Read on 2026-09-29; for current roles see Affiliations above. Read at: metistechbio.com ↗ · metistechbio.com ↗
Founded
METiS TechBioDrug discovery · 2020 · 7 rounds on record · disclosed CNY 400M + $250M · IPO about HK$2.113B grossBackground: US National Academy of Engineering member; formulation roles at Merck and AstraZeneca (as the company's own announcements put it)
Co-founders: Caida Lai, Wenshou Wang
Backed byBeijing Pharma & Health Industry Investment FundDaxing District Industry Investment FundCICC Capital fundPICC CapitalChina Life EquitySequoia China
Nothing else on the record names them yet.
Something wrong or missing on this page? Tell me and it will be fixed or removed. Contact →